Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.47 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.47 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999120 | 0.83 | HTT (0.69) | CYP2D6CYP2C9CYP2C19GAATSHR | |
| SCHEMBL1576773 | 0.83 | CYP2D6 (0.71) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL14679114 | 0.81 | CYP2D6 (0.73) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL15153463 | 0.80 | CYP2D6 (0.71) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL3117145 | 0.80 | CYP2D6 (0.67) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL22982001 | 0.77 | MAPT (0.52) | GAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL12228180 | 0.75 | POLB (0.66) | CYP2D6CYP2C9CYP2C19GAATSHR | |
| SCHEMBL2994129 | 0.74 | TSHR (0.49) | CYP2D6CYP2C9CYP2C19GAATSHR | |
| SCHEMBL31448278 | 0.74 | CYP2D6 (0.55) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 | |
| SCHEMBL2233620 | 0.74 | CYP2D6 (0.58) | CYP2D6HDAC8HDAC6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | CYP2D6 37/4885HDAC8 705/4885HDAC6 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.